Modular gRNA synthesis unlocks next-gen CRISPR therapies
Wednesday, October 22, at 15:00 GMT | 16:00 CET | 10:00 EDT | 7:00 PDT
Glioblastoma (GBM) is an aggressive brain tumor, with a five-year survival rate of just 5.5%. Its highly suppressive tumor microenvironment (TME) presents a significant barrier to CAR-T therapy. However, advances in multiplex gene editing and machine learning are creating new opportunities for effective solid tumor cell therapies.
Join us for this two-part webinar to discover how cutting-edge CAR-T engineering is using multiplex base editing and the gRNA technology to overcome these challenges.
Part 1: KiraGen Bio’s 5-KO TME-Guard CAR-T Cells and KiraLOGIC Platform
- Learn how multiplex gene editing is enabling CAR-T therapies designed to overcome the immunosuppressive TME
- See real-world data demonstrating durable tumor control in aggressive GBM models
- Understand the critical role of GenScript’s high-performance sgRNA in enabling these breakthroughs
Part 2: GenScript’s OmniGuide RNA – Versatile guide RNA for any gene editing need
- Explore OmniGuide, a single platform offering the longest and most versatile synthetic gRNA on the market (up to 266 nt!)
- Explore a platform compatible with all gene editing systems, including base and prime editing
- From research use only (RUO) to cGMP-ready applications
Key learning objectives:
- Learn how next-gen CAR-Ts are tackling previously 'undruggable' tumors
- Discover how OmniGuide RNA can supercharge your gene editing pipeline
- Get exclusive insights from pioneers in cell therapy and CRISPR
Who should attend?
- Academic researchers who use, or are interested in, gene editing
- Biotech/biopharma scientists developing CRISPR-based cell and gene therapies
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Dr. Ryan Murray is the Co-Founder and Chief Scientific Officer of KiraGen Bio, where he leads the development of AI-driven, multiplex gene-edited CAR-T cell therapies to overcome the immunosuppressive tumor microenvironment (TME) in solid tumors. With over a decade of experience in cellular engineering, synthetic biology, and gene editing, he has contributed to cutting-edge cell therapy programs at bluebird bio and Beam Therapeutics. His PhD from Northeastern University focused on TME-mediated resistance in NSCLC, shaping KiraGen’s strategy to engineer next-generation TME-resistant CAR-T cells.
Scott Pritchett is the Senior Global Market Development Manager at GenScript, where he manages the strategy and growth of the gene editing portfolio. His work spans OmniGuide synthetic gRNA, HDR templates, online design tools, CRISPR libraries, CRISPR plasmids, and other advanced solutions that empower researchers worldwide to drive innovation in genome engineering.
Moderator
